Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer

Key Points

• The study aims to investigate the trends in utilization of first-line targeted therapies for metastatic breast cancer and the associated racial disparities.
• Examined utilization trends of CDK4/6 inhibitors and pertuzumab in metastatic breast cancer.
• Identified racial disparities between non-Hispanic Black (NHB) and non-Hispanic White (NHW) patients.
• Performed data analysis on therapy utilization rates over time.
• NHB patients were less likely to receive CDK4/6 inhibitors compared to NHW patients.
• About 50% of eligible patients did not receive pertuzumab.
• Further research is needed to understand factors leading to the underutilization of these therapies among different racial groups.